2020/09/02
The Japanese Foundation for Cancer Research
The Institute of Medical Science, The University of Tokyo
Sapporo Medical University
Keio University Hospital
Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion
NanoCarrier Co., Ltd.
Japan Agency for Medical Research and Development (AMED)
On September 2, 2020, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (hereafter "CIH") began an investigator-initiated clinical trial (First-in-Human trial) using the siRNA nucleic acid drug candidate for breast cancer (SRN-14/GL2-800). This drug has been jointly developed with The Institute of Medical Science, The University of Tokyo; Sapporo Medical University; the Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion (hereafter "iCONM"); Keio University Hospital; and NanoCarrier Co., Ltd. (AccuRna, Inc. at the time of development).
Please see below for the full press release.